• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

放射性碘治疗甲状腺乳头状癌。

Radioactive Iodine for Papillary Thyroid Carcinoma.

机构信息

Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong.

出版信息

Methods Mol Biol. 2022;2534:225-241. doi: 10.1007/978-1-0716-2505-7_16.

DOI:10.1007/978-1-0716-2505-7_16
PMID:35670979
Abstract

Radioactive iodine is given after total thyroidectomy for remnant ablation or treatment of residual/metastatic disease. The decision and dose of radioactive iodine should be in a personalized and patient-specific approach, taking account the clinical-pathological features, risk stratification, patient's preference, and facilities of the institutions. We review the principles and use of radioactive iodine in differentiated thyroid cancer.

摘要

放射性碘在甲状腺全切术后用于残余消融或治疗残留/转移性疾病。放射性碘的决策和剂量应采用个性化和患者特异性的方法,考虑临床病理特征、风险分层、患者偏好和医疗机构的设施。我们回顾了分化型甲状腺癌中放射性碘的原则和应用。

相似文献

1
Radioactive Iodine for Papillary Thyroid Carcinoma.放射性碘治疗甲状腺乳头状癌。
Methods Mol Biol. 2022;2534:225-241. doi: 10.1007/978-1-0716-2505-7_16.
2
Predictors of recurrence after total thyroidectomy plus neck dissection and radioactive iodine ablation for high-risk papillary thyroid carcinoma.高危型甲状腺乳头状癌行甲状腺全切除术加颈部淋巴结清扫和放射性碘消融术后复发的预测因素。
J Surg Oncol. 2020 Oct;122(5):906-913. doi: 10.1002/jso.26090. Epub 2020 Jun 25.
3
Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.嗜酸细胞性甲状腺乳头状癌和嗜酸细胞性甲状腺低分化癌:临床特征、摄取、对放射性碘治疗的反应和结局。
Front Endocrinol (Lausanne). 2021 Dec 16;12:795184. doi: 10.3389/fendo.2021.795184. eCollection 2021.
4
The impact of radioactive iodine treatment on survival among papillary thyroid cancer patients according to the 7th and 8th editions of the AJCC/TNM staging system: a SEER-based study.基于 SEER 数据库的研究:第 7 版和第 8 版 AJCC/TNM 分期系统中放射性碘治疗对甲状腺乳头状癌患者生存的影响。
Updates Surg. 2020 Sep;72(3):871-884. doi: 10.1007/s13304-020-00773-y. Epub 2020 Apr 27.
5
[Ectopic thyroid tissue with a primary carcinoma].[伴有原发性癌的异位甲状腺组织]
Ugeskr Laeger. 2017 Mar 20;179(12).
6
Prophylactic central lymph node dissection informs the decision of radioactive iodine ablation in papillary thyroid cancer.预防性中央淋巴结清扫术为甲状腺乳头状癌放射性碘消融治疗提供决策依据。
Am J Surg. 2021 May;221(5):886-892. doi: 10.1016/j.amjsurg.2020.08.012. Epub 2020 Aug 18.
7
An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer.一项最新的系统评价与述评,探讨放射性碘残留消融术在分化型甲状腺癌中的有效性。
Endocrinol Metab Clin North Am. 2008 Jun;37(2):457-80, x. doi: 10.1016/j.ecl.2008.02.007.
8
Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine.应用美国甲状腺协会的新指南导致甲状腺全切术的完成率大幅提高,以便进行辅助放射性碘治疗。
Surgery. 2017 Jan;161(1):127-133. doi: 10.1016/j.surg.2016.05.056. Epub 2016 Nov 14.
9
The rationale of patients with early-stage papillary thyroid cancer for accepting or rejecting radioactive iodine remnant ablation.早期乳头状甲状腺癌患者接受或拒绝放射性碘残留消融的基本原理。
Thyroid. 2013 Feb;23(2):246-7. doi: 10.1089/thy.2012.0422.
10
Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?对于 T1-2N1bM0 期甲状腺乳头状癌,不进行放射性碘治疗的手术切除是否是一种安全的替代治疗方法?
Auris Nasus Larynx. 2021 Feb;48(1):148-153. doi: 10.1016/j.anl.2020.07.005. Epub 2020 Jul 25.

引用本文的文献

1
Pure red-cell aplasia after radioactive iodine treatment in a patient with papillary thyroid cancer and follow up for two years: a case report.1例甲状腺乳头状癌患者放射性碘治疗后发生纯红细胞再生障碍性贫血并随访2年:病例报告
Front Oncol. 2025 Jun 24;15:1539586. doi: 10.3389/fonc.2025.1539586. eCollection 2025.
2
MAP17 contributes to the tumorigenesis of papillary thyroid carcinoma by activating the AKT signaling pathway.微管相关蛋白17通过激活AKT信号通路促进甲状腺乳头状癌的肿瘤发生。
Arch Endocrinol Metab. 2025 Mar 10;69(1):e240342. doi: 10.20945/2359-4292-2024-0342.
3
Is There a Role for Molecular Testing for Low-Risk Differentiated Thyroid Cancer? A Cost-Effectiveness Analysis.
低风险分化型甲状腺癌的分子检测是否有作用?一项成本效益分析。
Cancers (Basel). 2023 Jan 27;15(3):786. doi: 10.3390/cancers15030786.
4
Reminiscence therapy care program as a potential nursing intervention to relieve anxiety, depression, and quality of life in older papillary thyroid carcinoma patients: A randomized, controlled study.回忆疗法护理方案作为缓解老年甲状腺乳头状癌患者焦虑、抑郁及改善生活质量的一种潜在护理干预措施:一项随机对照研究。
Front Psychol. 2022 Nov 24;13:1064439. doi: 10.3389/fpsyg.2022.1064439. eCollection 2022.